Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.9K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

408
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
408
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

66
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
66
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

389
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
389
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

423
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
423
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality Measures in the Long-term and Post-acute Care Settings: A Narrative Overview.

The Senior care pharmacist·2025
Same author

Readiness, Reception, and Performance of Students in a Communications Course Delivered Amid the Pandemic.

American journal of pharmaceutical education·2021
Same author

Impact of pen utilization on insulin cost reduction in long-term care facilities.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2012
Same journal

Digging Deeper Into the Patient-Driven Payment Model.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same journal

Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same journal

Statins: The Burglar of Memory?

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same journal

Identifying Cognitive Impairment in an Older Adult Using Two Different Screening Tools.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same journal

Management of Primary Sjögren's Syndrome.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same journal

Increased Use of Medical Marijuana: Skepticism vs. Evidence.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Key Value Considerations for Consultant Pharmacists.

Lee Meyer1, Ronald G Perry, Susan M Rhodus

  • 1M2:Pharmacist Services, Irvine, California, USA.

The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
|July 15, 2016
PubMed
Summary
This summary is machine-generated.

This article offers long-term care business strategies for pharmacy providers to improve profitability and resident drug therapy during care transitions. Experts share insights on cost control, medication management, and collaboration for better outcomes.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.2K

Related Experiment Videos

Last Updated: Mar 17, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.2K

Area of Science:

  • Pharmacy Practice
  • Health Services Research
  • Geriatric Pharmacy

Background:

  • Managing resident drug regimens in long-term care and during transitions is complex.
  • Efficiency and cost control are critical for pharmacy providers in various care settings.

Purpose of the Study:

  • To provide key long-term care business strategies for pharmacy providers.
  • To enhance profitability while ensuring optimal resident therapy during care transitions.

Main Methods:

  • Expert insights from four pharmacy management specialists.
  • Discussion of critical pharmacy practice issues including formulary management, performance metrics, and dispensing.
  • Focus on cost-control measures, billing, medication reconciliation, and transitions of care.

Main Results:

  • Strategies for accessing and utilizing critical information to improve care processes.
  • Insights into challenges and solutions for short-cycle dispensing.
  • Guidance on effective collaboration between pharmacy providers, facility staff, and consultant pharmacists.

Conclusions:

  • Implementing strategic business practices can improve pharmacy profitability in long-term care.
  • Collaborative approaches are essential for optimizing resident medication therapy across care transitions.
  • Actionable ideas are provided for improving overall pharmacy care processes and resident outcomes.